Pomegra
Illumina (ILMN) stock fell 18.6% to $235.99 on Oct. 30, its worst session since 2016, despite a Q3 earnings beat and a raised full-year 2026 revenue forecast.
- Illumina closed at $235.99 on Oct. 30, down 18.6% from $290.06, its steepest one-day fall since October 2016.
- Q3 adjusted EPS of $1.44 beat the $1.36 estimate, but revenue of $1.13 billion fell short of the roughly $1.15 billion estimate.
- Full-year 2026 revenue guidance rose to $4.64 billion-$4.66 billion, with the stock down sharply anyway.
Lead
Illumina shares dropped 18.6% on Friday, Oct. 30, the session after the genomic sequencing company reported third-quarter results. The decline was the stock's largest single-day loss in a decade and came after a gain of roughly 148% over the previous 12 months. The S&P 500 fell 1.8% the same day as disappointing results from Amazon (AMZN) and Intel (INTC) fed a selloff in artificial-intelligence stocks, while healthcare shares rose about 0.5%.What Happened to Illumina Stock After Earnings?
Illumina stock fell almost 19% in the session following its Oct. 29 report, after a quarter in which profit topped forecasts and revenue came in below them. Non-GAAP diluted earnings per share were $1.44, against a $1.36 estimate. GAAP diluted EPS was $1.43.
Reported revenue was $1.13 billion, up 4.2% from a year earlier. Excluding roughly $79 million in tariff refund benefits tied to IEEPA duties, of which $37 million was credited to customers, revenue was $1.17 billion, up 4.7%. GAAP operating margin was 27.0%, and the non-GAAP margin excluding the tariff benefit was 25.0%, about 100 basis points above guidance. Cash and short-term investments stood at $1.34 billion.
Why Did Illumina Shares Fall Despite Raised Guidance?
The sell-off followed a revenue miss, a valuation that had expanded through a year-long rally, and fresh uncertainty over China, all landing in a weak tape for growth stocks.
The company lifted its 2026 revenue range by $30 million at the midpoint, to $4.64 billion-$4.66 billion, and set non-GAAP EPS guidance at $5.40-$5.45 with an operating margin of about 23.6%. Fourth-quarter revenue is guided to $1.22 billion-$1.24 billion. The outlook sat above prior guidance, but the stock had already priced in strong execution, leaving little room for a top-line shortfall.
China added to the pressure. Management said it learned of new U.S. trade restrictions on Chinese competitors on the morning of the earnings call, including a Department of Homeland Security import bar on products from rival sequencer maker MGI. Illumina has faced its own restrictions in China since 2025, when Beijing placed it on its unreliable entity list and barred imports of its sequencers. The company said it intends to keep serving Chinese customers while working with local regulators. Organic growth of 4.7% excludes Greater China, which remains a swing factor for reported results.
Strategic Context: Clinical Demand and NovaSeq X
Clinical sequencing and the NovaSeq X platform were the main drivers of the quarter. Illumina placed more than 80 NovaSeq X instruments in Q3, bringing placements over four quarters to about 360 units, ahead of the pace of the platform's first year. Clinical consumables in the rest of the world grew 14%, and management kept its expectation of mid-teens clinical growth for 2026.
Conversion of research and applied volume to NovaSeq X has stayed above 90% for five consecutive quarters, which management described as largely complete and which reduces pricing pressure from the older platform. Clinical conversion stands at 78%, as some customers keep legacy systems for existing assays while adding X capacity for new tests. The company is also building its Billion Cell Atlas, a dataset aimed at AI and predictive biology applications, which management said is more than halfway complete.
What Comes Next for Illumina in 2027?
Illumina's next catalyst is its fourth-quarter report, when management has said it will provide 2027 guidance. The company says it remains on track to meet its long-range financial targets, and operating margin has expanded about 400 basis points since 2024.
Three variables will shape the path. First, whether underlying ex-China growth holds near the mid-single-digit pace reported in Q3. Second, how the new U.S. restrictions on Chinese rivals and Beijing's existing curbs on Illumina affect Greater China revenue. Third, whether clinical placements keep translating into recurring consumables sales as the research conversion cycle matures.
Outlook
Illumina ended a volatile session 18.6% lower despite beating on earnings, raising guidance and reporting stronger margins. The move reflected a revenue shortfall against estimates, a stock that had more than doubled in a year, and China-related uncertainty, in a market sell-off led by technology. The Q4 report and 2027 outlook are the next tests of whether clinical demand and NovaSeq X adoption can sustain growth.
